Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca

BACKGROUND: OTX-101 is approved for treatment of keratoconjunctivitis sicca (KCS). We present results of a phase 3 worse-eye efficacy analysis and 1-year safety extension. METHODS: During the double-masked treatment phase, patients with bilateral KCS were randomized 1:1 to 12 weeks OTX-101 or vehicl...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheppard, John, Bergmann, Mark, Schechter, Barry A, Luchs, Jodi, Ogundele, Abayomi, Karpecki, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811471/
https://www.ncbi.nlm.nih.gov/pubmed/33469259
http://dx.doi.org/10.2147/OPTH.S279364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811471/
https://www.ncbi.nlm.nih.gov/pubmed/33469259
http://dx.doi.org/10.2147/OPTH.S279364

Ejemplares similares